Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Head & Neck 2Genitourinary 2Endocrine 2

Conditions

Neuroendocrine Tumors 208Multiple Endocrine Neoplasia Type 1 130Thyroid Cancer, Papillary 78Pituitary Neoplasms 70Thyroid Neoplasms 59Pheochromocytoma 55Carcinoma, Neuroendocrine 49Neoplasms 48Carcinoid Tumor 48Carcinoma, Medullary 35Adrenocortical Carcinoma 35Adenocarcinoma, Follicular 34Pancreatic Neoplasms 33Thyroid Carcinoma, Anaplastic 30Neoplasm Metastasis 27Carcinoma, Non-Small-Cell Lung 27Insulinoma 26Breast Neoplasms 25Paraganglioma 24Melanoma 23Colorectal Neoplasms 23Colonic Neoplasms 23Carcinoma, Renal Cell 23Adenoma, Islet Cell 23Somatostatinoma 22Adrenal Gland Neoplasms 22Sarcoma 21Carcinoma, Islet Cell 21Prostatic Neoplasms 20Glucagonoma 19

Interventions

GSK3352589 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Irritable Bowel Syndrome × Endocrine × Clear all
NCT03154086 2019-08-09

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

GlaxoSmithKline

Phase 1 Completed
68 enrolled 80 charts
Endocrine

Multiple Endocrine Neoplasia Type 2a, Irritable Bowel Syndrome

NCT02727283 2017-05-08

A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers

GlaxoSmithKline

Phase 1 Completed
16 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 2a, Irritable Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡